Drug Approval | December 22, 2025
Granules receives FDA tentative approval for generic Amphetamine ER orally disintegrating tablets
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The expansion includes a larger technical and service team and increased local procurement
The state-of-the-art facility is expected to be commissioned over the next three years
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The move strengthens GBL’s clinical-stage presence in the United States
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Subscribe To Our Newsletter & Stay Updated
